Serum Cytokine Profile in Adalimumab-treated Refractory Uveitis Patients: Decreased IL-22 Correlates with Clinical Responses. (June 2013)

• Record Type: Journal Article
• Authors: Cordero-Coma, Miguel; Calleja, Sara; Llorente, Milagros; Rodriguez, Esther; Franco, Manuel; Ruiz de Morales, Jose G.
• Is Part Of: Ocular immunology and inflammation. Volume 21:Number 3(2013)
• Page Start: 212
• Page End: 219
• Publication Date: 2013-06
• Subjects: Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.3109/09273948.2013.770888
• Languages: English
• ISSNs: 0927-3948

Abstract

<abstract> <title>Abstract</title> <p> <italic>Purpose</italic>: To report the effect of adalimumab on serum cytokines in chronic refractory uveitis.</p> <p> <italic>Methods</italic>: Prospective study on the effects of adalimumab on serum cytokine levels at different time points in a cohort of 12 refractory chronic uveitis patients. Results were analyzed according to clinical outcomes and compared with systemic steroid-treated recurrent uveitis patients.</p> <p> <italic>Results</italic>: Before treatment, patients exhibited significantly increased IL-1β, IL-6, TNFα, IL-12 p70, IL-10, and IL-22. Adalimumab significantly decreased IL-6, and IL-12p70 at early time points (after 1 month of treatment). Adalimumab effects on IL-10 and IL-22 appeared later (after 6 months of treatment). IL-1β, IL-17A, and TNFα were not modified at any time point. Only decreased IL-22 serum levels correlated with disease activity (<italic>p</italic> = 0.011). These effects were not observed in steroid-treated patients.</p> <p> <italic>Conclusions</italic>: Adalimumab induced drug-specific and time-dependent declines in serum levels of particular cytokines, although only IL-22 correlated with disease activity in 10 out 12 patients.</p> </abstract>